HealthTree Logo HealthTree Foundation
Donate

Notifications

You're all caught up

HealthTree Logo
Donate
Personal Health Record
  • My Feed
  • Recently viewed

Learn

  • Topics
  • Events

Explore

  • Find treatments & trials
  • Participate in research
  • Find a coach
  • Find a specialist
  • Talk to a patient navigator
  • Get involved
  • For researchers
  • For healthcare providers
  • About us
  • Get involved
  • For researchers
  • For healthcare providers
  • About us

Create your Personal Health Record and unlock support built around you

Aligned with your diagnosis, treatment and where you are in your care. It lets HealthTree show you:

  • Treatments and trials you qualify for
  • Education for your stage of care
  • Financial support for your medications
  • Solutions to your side effects
Trial match for you
Matched on subtype and prior lines
Financial help
Support program for your current medication
Coach support
Coach suggestion with your same treatment path
Learn more about HealthTree
Trial match for you
Matched on subtype and prior lines
Financial help
Support program for your current medication
Coach support
Coach suggestion with your same treatment path
Video

BETA - What is the Talisman Study? What is the Waterless Empirical Taste Test?

Posted by
HealthTree Logo HealthTree
• June 15, 2026

Description

What is the Talisman Study? What is the Waterless Empirical Taste Test?

On this video

Healthtree contact Samantha Shenoy, NP

Samantha Shenoy, NP

Healthtree contact Ajai Chari, MD, Specialist

Ajai Chari, MD, Specialist

UCSF Helen Diller Family Comprehensive Cancer Center

Related Content

  • Video Iberdomide Plus Dara After Transplant: Early Safety and Results | IMS 2026
  • Video ENDURANCE Trial: Can Myeloma Patients Stop Revlimid Maintenance After 2 Years? | IMS 2026
  • Video Multiple Myeloma Side Effects: When Should You Call Your Care Team? | IMS 2026
  • News Mosunetuzumab Combination May Expand Earlier Follicular Lymphoma Treatment Options
  • Video Does Intensive Treatment Affect Quality of Life in High-Risk Myeloma? | RADAR Trial | IMS 2026